IC
CRL icon

Inscription Capital’s Charles River Laboratories CRL Stock Holding History

Inscription Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$767K Sell
3,383
-55
-2% -$9.79K 0.07% 267
2026
Q1 		$593K Sell
3,438
-1,991
-37% -$369K 0.06% 312
2025
Q4 		$1.08M Sell
5,429
-467
-8% -$84.7K 0.11% 175
2025
Q3 		$922K Buy
5,896
+3,827
+185% +$608K 0.1% 211
2025
Q2 		$314K Buy
+2,069
New +$276K 0.05% 348

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Inscription Capital's CRL Position: Q2 2026 in Review

Inscription Capital reduced its Charles River Laboratories (CRL) stake by 1.6% in Q2 2026, selling an estimated $9.79K and leaving 3,383 shares worth $767K. The position accounts for 0.07% of the portfolio, ranked #267.

Inscription Capital first reported a position in CRL in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.08M in Q4 2025. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Inscription Capital held 3,383 shares of Charles River Laboratories worth $767K as of Q2 2026.
  • Inscription Capital sold 55 Charles River Laboratories shares in Q2 2026, an estimated $9.79K.
  • Charles River Laboratories made up 0.07% of Inscription Capital's portfolio in Q2 2026, its #267 holding.
  • Inscription Capital first reported a position in Charles River Laboratories in Q2 2025 and has held it in 5 quarters since.
  • Inscription Capital's Charles River Laboratories position peaked at $1.08M in Q4 2025.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.